Emyria Ltd (emd) Logo

Emyria Ltd (EMD)

___:___ · Healthcare

EMD Chart


EMD's Principal Activity is the provide care for its patients through Emeralds specialist clinics whilst gathering Real-World-Evidence (RWE) insights in relation to novel therapies such as medicinal cannabinoids and drug development.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) +34.53%
vs ASX 200 (1yr) +31.44%


Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 1,111 of 2,415
Sector Rank 88 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies MX1 / BMT / IVX
EPS -$0.027
DPS $0.00
Book Value Per Share $0.03

Broker Consensus

EMD is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

Emyria Limited (EMD, formerly Emerald Clinics Limited) operates a Real-World Evidence using its network of specialist medical clinics and purpose-built, remote patient monitoring software and technology to gather high quality clinical data from informed and consenting patients. EMD's model provides a clinical services and healthcare technology that focused on the provision of care for patients clinically determined to have exhausted conventional therapies and who may be suitable for cannabinoid-based medicines.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office West Leederville WA 6007
Website www.emyria.com
Registry Automic Group
Auditor Stantons International Audit & Consulting Pty Ltd
Date Listed 12 Feb 2020

Upcoming Calendar (Forecasted)

Date Event
30/08/2022 Report (Prelim)
30/09/2022 Report (Annual)
27/02/2023 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr Karen Smith Non-Executive Director Nov 2021

Dr Karen Smith

Non-Executive Director

Dr Smith has overseen more than 100 clinical trials and more than 20 regulatory approvals leading to product launches across diverse therapeutic areas including neuroscience, rare disease, oncology, cardiology, dermatology, oncology and anti-infectives. In addition to R&D and pipeline development, her experience includes the acquisition of U.S. and international companies, divestitures and negotiating partnership deals between biotech and pharma. Dr Smith was recently Chief Medical Officer of Emergent BioSolutions. Dr Smith is also a Director at Antares Pharmaceuticals - developing novel drug delivery technologies and Sangamo Therapeutics and Acceleron Pharmaceuticals - both developing novel treatments for rare diseases, and TeeFib - developing novel treatments for Fibrosis. Previously, Dr Smith served as Executive Vice President, Global Head R&D and Chief Medical Officer of Jazz Pharmaceuticals, Inc. She was also the founding CEO of the Minderoo Foundation's Eliminate Cancer Initiative supported by Andrew Forrest and remains an advisor to that program. She has also held senior leadership positions at Allergan plc, AstraZeneca and Bristol-Myers Squibb.

Sir John Tooke Non-Executive Director Feb 2020

Sir John Tooke

Non-Executive Director

Sir Tooke is Executive Chairman of Academic Health Solutions, a start-up Group offering advice to clients internationally on medical research and health service transformation. He is Senior Independent Director at BUPA Chile and was until 2019 non-executive director of the BUPA main Board and the Chair of the Medical Advisory Council. He is the Chair of Collaboration for the Advancement of Medical Innovation (CASMI) UCL and Chaired the Oversight Group for the Academy of Medical Sciences project. He also served as an Review Board Member for Google Health (UK). Sir Tooke was Head of the School of Life and Medical Sciences at University College London (UCL) as Vice Provost (Health) and Academic Director of UCL Partners from 2010 - 2015. He is the Past President of the Academy of Medical Sciences in the UK. Sir Tooke has 30 years experience as a consultant physician specialising in diabetes, endocrinology, vascular medicine and internal medicine with research experience (basic biomedical, medicine, and health research and also includes improvement science) recognised through Fellowship of the Academy of Medical Sciences. He held a Board position at the Francis Crick Institute (2011 - 2015) and was a Member of the Council for Science & Technology (2011-2015) reporting to the Prime Minister (UK).

Dr Michael Winlo Managing Director Nov 2019

Dr Michael Winlo

Managing Director

Dr Winlo was CEO at Linear Clinical Research Ltd (Linear) until October 2019, a company that provides clinical trial services for US and Asia-based biotech companies. Linear adopt electronic data capture technology. Dr Winlo retains a Directorship at Linear. Prior to Linear, He was Health Lead at Palantir Technologies, a Big Data company based in Silicon Valley California.

Dr Alistair Vickery Executive Director Nov 2018

Dr Alistair Vickery

Executive Director

Dr Vickery has expertise in clinical practice, health service management, clinical and educational research and board director skills. He is adjunct Clinical Professor of Primary Health Care at the University of Western Australia and Notre Dame University. He is the clinical lead of the research group CHASM (The Collaborative for Health Care Analysis and Statistical Modelling) which provides analysis modelling to inform clinical service planning and service evaluation. He is Board Chair of Black Swan Health, one of NFP health care service providers in Western Australia.

Mr Matthew (Matt) Callahan Non-Executive Director Mar 2018

Mr Matthew (Matt) Callahan

Non-Executive Director

Mr Callahan is a life sciences executive with experience. He has been the founder, CEO or Executive Director of a number of pharmaceutical and health tech companies which includes Churchill Pharma Inc. He has led the development of four pharmaceutical products that have received FDA approval and he has more than 25 years legal, IP and investment management experience. Mr Callahan has worked as an investment director for two venture capital firms investing in lifesciences, technology and other sectors.

Dr Stewart James Washer Executive Chairman,Executive Director Mar 2018

Dr Stewart James Washer

Executive Chairman,Executive Director

Dr Washer has 25 years of CEO and Board experience in medical and agrifood biotech companies. Stewart has held a number of Board positions in the past, including Chairman of Hatchtech Pty Ltd that was sold in 2015 for A$279m and was a director of iCeutica that was sold to a US Pharma. He was also a Senator with Murdoch University and was a Director of AusBiotech Ltd.

Mr Simon Lee Robertson Company Secretary N/A
Su-Mei Sain Chief Financial Officer N/A
Patrizia Washer Research Manager N/A

Director Transactions

EMD directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
19/04/22 Michael Winlo Buy +60,000 $0.318 $19,089 On-market trade
06/12/21 Karen Smith Issued 550,000 $0.365 $200,750 Issue of securities
13/11/20 John Tooke Issued 1,000,000 $0.076 $76,000 Issue of options
13/11/20 Matthew (Matt) Callahan Issued 1,500,000 $0.076 $114,000 Issue of options
13/11/20 Alistair Vickery Issued 2,000,000 $0.076 $152,000 Issue of options
13/11/20 Michael Winlo Issued 4,000,000 $0.076 $304,000 Issue of options
12/11/20 Stewart Washer Buy +255,000 $0.08 $20,321 On-market trade
11/11/20 Stewart Washer Buy +150,000 $0.082 $12,283 On-market trade
10/11/20 Stewart Washer Buy +100,000 $0.08 $7,986 On-market trade
09/11/20 Stewart Washer Buy +270,000 $0.077 $20,765 On-market trade
19/10/20 Alistair Vickery Buy +128,000 $0.078 $10,002 On-market trade
16/03/20 Stewart Washer Buy +100,000 $0.061 $6,110 On-market trade
16/03/20 Stewart Washer Buy +100,000 $0.061 $6,110 On-market trade
10/03/20 Stewart Washer Buy +58,500 $0.09 $5,290 On-market trade
09/03/20 Stewart Washer Buy +120,500 $0.089 $10,668 On-market trade
06/03/20 Stewart Washer Buy +271,499 $0.089 $24,182 On-market trade
06/03/20 Stewart Washer Buy +271,499 $0.089 $24,182 On-market trade

Director Interests

The current holdings of EMD directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Michael Winlo 19/04/2022 60,000 N/A 7,500,000 N/A
Karen Smith 06/12/2021 550,000 N/A 1,500,000 N/A
Alistair Vickery 30/06/2021 N/A 128,000 4,000,000 N/A
John Tooke 30/06/2021 N/A N/A 1,500,000 N/A
Stewart Washer 30/06/2021 N/A 49,325,589 N/A N/A
Matthew (Matt) Callahan 30/06/2021 N/A 19,600,000 1,500,000 N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Sep 20, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Dr Stewart James Washer & Dr Patrizia Derna Washer 28,400,000 11.18%
Mal Washer Nominees Pty Ltd 19,600,000 7.71%
Mercator Shipwrights Pty Ltd 19,600,000 7.71%
Mr Craig Lawrence Darby 19,600,000 7.71%
Mr Sufian Ahmad 10,276,210 4.04%
Miss Sihong Zeng 6,523,385 2.57%
Ms Chunyan Niu 5,882,546 2.32%
Lakewest Pty Ltd 5,731,960 2.26%
Mr Stephen Peter Somerville 4,900,000 1.93%
Rimoyne Pty Ltd 3,831,244 1.51%
Woodlands Opportunity Fund Pty Ltd 3,551,757 1.40%
Mr Bilal Ahmad 3,450,000 1.36%
Mr Pak Lim Kong 3,416,667 1.34%
Kobala Investments Pty Ltd 2,600,000 1.02%
Mr Lim Pak Kong 2,370,930 0.93%
Mr Craig Lawrence Darby i 2,000,000 0.79%
Adam James(Araucaria A/C) 1,960,000 0.77%
D Schecter Medicine Professional Corporation 1,960,000 0.77%
Cs Fourth Nominees Pty Limited 1,683,576 0.66%
Canopy Growth Corporation 1,562,500 0.61%
Diab Investments Pty Ltd 1,554,622 0.61%
Mr Boyun Liu 1,549,962 0.61%
Dr Stewart James Washer & Dr Patrizia Derna Washer i 1,325,599 0.52%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 22 357 344 716 233 1,672

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Tattarang Ventures Pty Ltd 24/11/2021 20,000,000 7.29
Stewart James Washer 24/11/2021 48,550,499 17.99
Craig Lawrence Darby 24/11/2021 22,709,790 8.28
Mal Washer Nominees Pty Ltd 24/11/2021 19,600,000 7.15
Mercator Shipwrights Pty Ltd 24/11/2021 19,600,000 7.15

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
24-11-21 Tattarang Ventures Pty Ltd 20,000,000 -- 7.29

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $0.175 30 June
2020 $0.048 30 June
EMD Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.